WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
AstraZeneca secured a Federal Court injunction in Australia blocking Pharmacor from selling generic dapagliflozin while a ...
Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or ...
On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
BREZTRI, already approved in over 80 countries for chronic obstructive pulmonary disease (COPD), may now offer hope to asthma sufferers. “We are excited by the positive results from the KALOS and ...
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic ...
Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri ...
In a Breztri commercial that launched a year ago, a man using the AstraZeneca COPD inhaler was able to participate in hiking and other outdoor activities via an RV road trip. In this year’s spot, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results